A rare case of phenobarbital-induced leukocytoclastic vasculitis
DARU Journal of Pharmaceutical Sciences · 2024
DOI: 10.1007/s40199-024-00515-0 ↗Kurz gefasst
Fallbericht in der Zeitschrift DARU Journal of Pharmaceutical Sciences, 2024. Verfasst von Zaruhi Kalikyan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergy, Yerevan State Medical University After Mkhitar Heratsi, Koryun Str. 2, Yerevan, Republic of Armenia. z…. Hauptthemen laut MEDLINE: Phenobarbital, Vasculitis, Leukocytoclastic, Cutaneous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Drug hypersensitivity reactions (DHRs) manifested as vasculitis are rare. Antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), sulphonamides, diuretics, immunosupressants and anticonvulsants are the most common culprits for drug-induced leukocytoclastic vasculitis (LCV) but there is scarce information about barbiturates. We present a case of 53-year-old female with severe vasculitis after phenobarbital- and NSAIDs-containing medications use. The preliminary diagnosis of drug-induced vasculitis was made based on anamnestic and clinical data. Further examinations confirmed the diagnosis of LCV and excluded other more common causes of vasculitis. The causative significance of used medications was assessed by long-term observation of the patient after the reaction, including the drug challenge series and Naranjo's Adverse Drug Reaction Probability Scale. It was concluded that phenobarbital is the most probable culprit drug. The patient's data were included in the Armenian Registry of Patients with Severe DHRs. Since then, the patient has avoided only barbiturate-containing drugs and no reactions were noted. Thus, the case indicates that even with limited diagnostic capabilities, the final diagnosis of rare drug-induced LCV and even rarer culprit drug can be established by comparing the available data. Awareness about phenobarbital and proper recording of the case are important in the management and prevention of DHRs manifested as vasculitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Allergy, Yerevan State Medical University After Mkhitar Heratsi, Koryun Str. 2, Yerevan, Republic of Armenia. zkalikyan@yandex.ru.
- Department of Clinical Immunology and Allergy, Yerevan State Medical University After Mkhitar Heratsi, Koryun Str. 2, Yerevan, Republic of Armenia.
Zitieren
APA
Kalikyan, Z., & Hakobyan, A. (2024). A rare case of phenobarbital-induced leukocytoclastic vasculitis. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1007/s40199-024-00515-0
Vancouver
Kalikyan Z, Hakobyan A. A rare case of phenobarbital-induced leukocytoclastic vasculitis. DARU Journal of Pharmaceutical Sciences. 2024. doi:10.1007/s40199-024-00515-0
BibTeX
@article{Kalikyan2024,
author = {Kalikyan, Zaruhi and Hakobyan, Armine},
title = {A rare case of phenobarbital-induced leukocytoclastic vasculitis},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2024},
doi = {10.1007/s40199-024-00515-0}
}
EUVIMED